PIERGENTILI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.090
EU - Europa 6.504
AS - Asia 5.534
SA - Sud America 633
AF - Africa 222
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 39
Totale 27.071
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.647
CN - Cina 2.284
SG - Singapore 1.586
RU - Federazione Russa 1.498
IT - Italia 1.172
DE - Germania 1.053
BR - Brasile 530
VN - Vietnam 472
PL - Polonia 457
HK - Hong Kong 442
GB - Regno Unito 396
UA - Ucraina 394
SE - Svezia 391
CA - Canada 369
FI - Finlandia 355
FR - Francia 337
ZA - Sudafrica 166
TR - Turchia 161
KR - Corea 141
IN - India 119
IE - Irlanda 104
CZ - Repubblica Ceca 86
JP - Giappone 72
NL - Olanda 56
BE - Belgio 55
MX - Messico 48
AU - Australia 46
AR - Argentina 41
BD - Bangladesh 41
EU - Europa 37
ES - Italia 36
IQ - Iraq 33
IR - Iran 31
PK - Pakistan 28
EC - Ecuador 19
EG - Egitto 19
LT - Lituania 17
HR - Croazia 14
ID - Indonesia 14
AT - Austria 13
RO - Romania 13
AE - Emirati Arabi Uniti 12
SA - Arabia Saudita 12
CO - Colombia 10
UZ - Uzbekistan 10
VE - Venezuela 9
MA - Marocco 8
PH - Filippine 8
RS - Serbia 8
AL - Albania 7
CH - Svizzera 7
DZ - Algeria 7
JO - Giordania 7
PE - Perù 7
TW - Taiwan 7
CL - Cile 6
KE - Kenya 6
PT - Portogallo 6
AZ - Azerbaigian 5
BY - Bielorussia 5
GR - Grecia 5
IL - Israele 5
JM - Giamaica 5
MY - Malesia 5
PA - Panama 5
SN - Senegal 5
UY - Uruguay 5
HU - Ungheria 4
KG - Kirghizistan 4
KH - Cambogia 4
NP - Nepal 4
PY - Paraguay 4
TH - Thailandia 4
BG - Bulgaria 3
GE - Georgia 3
HN - Honduras 3
IS - Islanda 3
KZ - Kazakistan 3
QA - Qatar 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GT - Guatemala 2
LB - Libano 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PS - Palestinian Territory 2
AD - Andorra 1
AO - Angola 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
Totale 27.053
Salva come PNG Salva come JPEG
Città #
Dallas 1.321
Ashburn 1.090
Woodbridge 1.039
Jacksonville 956
Fairfield 955
Singapore 892
Chandler 756
Ann Arbor 599
Houston 574
San Jose 565
Wilmington 535
Hong Kong 429
Boardman 406
Beijing 391
Seattle 391
Nanjing 333
Warsaw 316
Cambridge 308
Los Angeles 239
Toronto 238
Dearborn 233
Camerino 209
New York 182
Helsinki 175
Ho Chi Minh City 171
The Dalles 158
Düsseldorf 153
San Mateo 152
Johannesburg 150
Seoul 138
Tongling 135
Kraków 129
Lawrence 128
Princeton 128
Lauterbourg 121
Columbus 120
Istanbul 119
Nanchang 116
Munich 107
Dublin 104
Hanoi 103
Moscow 100
Orem 100
Ogden 97
Buffalo 93
Kunming 86
London 86
Lachine 80
Shanghai 76
Milan 75
Shenyang 74
Santa Clara 70
Brno 66
Guangzhou 57
Jiaxing 57
Tokyo 55
Turku 54
São Paulo 53
Tianjin 53
Brussels 52
Jinan 50
Chicago 49
Council Bluffs 47
Venezia 45
Hebei 44
Chennai 42
Frankfurt am Main 42
Changsha 39
Hangzhou 36
San Diego 36
Philadelphia 34
Poplar 34
Redwood City 34
Manchester 33
Denver 32
Stockholm 32
Zhengzhou 32
Montreal 29
Wuhan 29
Washington 28
Brooklyn 27
Falls Church 27
Hefei 27
Rome 26
Boston 25
Leawood 25
Trieste 25
Da Nang 24
Nuremberg 24
Phoenix 24
Venice 24
Amsterdam 23
Taizhou 22
Centro 21
Ningbo 21
Sydney 21
Mumbai 20
Ascoli Piceno 19
Haiphong 19
Ankara 18
Totale 17.957
Salva come PNG Salva come JPEG
Nome #
1,4-Dioxane nucleus as a suitable scaffold in the building of ligands interacting with NMDA and σ1 receptors 628
1,4-DIOXANE NUCLEUS AS A SUITABLE SCAFFOLD FOR NOVEL D2-LIKE RECEPTOR LIGANDS 615
1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists 615
1,4-Dioxane ring as a promising template of novel 5-HT1A full agonists 551
1'-Benzyl-3,4-dihydrospiro[2H-1-benzothiopyran-2,4'-piperidine] (Spipethiane), a potent and highly selective sigma1 lingand 548
The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A Receptor 330
Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation 327
1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D4 Receptor 326
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring 303
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation 302
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 294
Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction 290
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 267
33rd camerino-Cyprus Symposium - Receptor Chemistry: Reality and Vision 264
Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions 264
Novel antitumor copper(ii) complexes designed to act through synergistic mechanisms of action, due to the presence of an NMDA receptor ligand and copper in the same chemical entity 262
Synthesis and antimuscarinic activity of derivatives of 2-substituted-1,3-dioxolanes 259
2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors 256
Investigation of the Role of Chirality in the Interaction with σ Receptors and Effect on Binge Eating Episode of a Potent σ1 Antagonist Analogue of Spipethiane 253
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement. 246
The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1A receptor over α1-adrenoceptor and D2-like receptor subtypes 240
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease 238
Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson's Disease or Schizophrenia 238
alpha(2)-Adrenoreceptors profile modulation. 2. Biphenyline analogues as tools for selective activation of the alpha2C-subtype 234
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 234
Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway 226
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites 225
Discovery of Highly Selective Imidazoline Receptor Ligands 222
Imidazoline binding sites (IBS) profile modulation: Key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues 218
33rd Camerino-Cyprus Symposium - Receptor Chemistry: Reality and Vision 218
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 216
Novel 1,4-dioxane derivatives as NMDA receptor channel blockers 216
77-LH-28-1 as a model for the rational design of selective dopamine D4 receptor ligands 213
Structure−Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11.1 Reversed Enantioselectivity of 1,4-Dioxane Derivatives in α1‑Adrenergic and 5‑HT1A Receptor Binding Sites Recognition 209
Role of the NMDA Receptor in the Antitumor Activity of Chiral 1,4-Dioxane Ligands in MCF-7 and SKBR3 Breast Cancer Cells 209
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 208
Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors 208
Rapid novel divergent synthesis and muscarinic agonist profile of all four optical isomers of N,N,N-trimethyl(6-methyl-1,4-dioxan-2-yl)methanaminium iodide. 207
Dopamine D-5 receptors: A challenge to medicinal chemists 207
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 206
Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane 206
Synthesis and muscarinic properties of (1S*,3R*,5R*)-trimethyl(1-methyl-6-oxabicyclo[3.1.0]hex-3-yl)methyl ammonium iodide 205
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 203
Design, Synthesis and Biological Evaluation of Novel Chemical Entities as Potential Anticancer Drugs and for the Control of the Metastatic Process 202
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 202
Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells 202
Homoazanicotine: A structure-affinity study for nicotinic acetylcholine (nACh) receptor binding 200
Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit an antidepressant-like effect 199
Roles of Wnt/β-catenin signalling pathway in the bony repair of injured growth plate cartilage in young rats 198
Use of frozen sections for the pharmacological characterization of compounds active on neurotransmitter receptors 196
28th Camerino-Cyprus-Noordwijkerhout Symposium - Trekking through Receptor Chemistry 195
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation 194
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 194
4WD to Travel Inside the 5-HT1A Receptor World 193
Potent muscarinic antagonists bearing 1,4-dioxane scaffold 192
Alpha(2)-Adrenoreceptors Profile Modulation. 3. (R)-(+)-m-Nitrobiphenyline, a New Efficient and alpha(2C)-Subtype Selective Agonist. 191
Topical antiinflammatory activity of complexes of escin and sterols with phospholipids. Part I. 191
Synthesis and Biological Evaluation of a Novel Series of Heterobivalent Muscarinic Ligands Based on Xanomeline and 1‑[3- (4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77- LH-28-1) 190
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 188
Solution-phase synthesis of ICG-001, a beta-turn peptidomimetic molecule inhibitor of beta-catenin-Tcf-mediated transcription 187
Enantioselective interactions to improve adrenergic α2C-agonism/α2A-antagonism 186
Might Adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine? 186
Muscarinic Thioligands with Cyclopentane Nucleus 186
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity 185
Allyphenyline analogues potentially useful in the management of chronic pain and opioid addiction. 183
Novel Potent 5-HT1a Agonists Selective over alpha1-Adrenoceptor Subtypes 183
Inhibition of WNT-β-catenin signalling promotes cartilage repair at injured growth plate in young rats 180
Synthesis, Absolute Configuration, and Biological Profile of the Enantiomers of trans-[2-(2,6-Dimethoxypheoxy)ethyl] [(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (Mephendioxan), a Potent Competitive alpha 1A-Adrenoreceptor Antagonist 179
Chain-lengthened and imidazoline analogues of nicotine 179
Synthesis and dopamine receptor affinities of 2-(4-fluoro-3-hydroxyphenyl)ethylamine and N-substituted derivatives 179
Novel muscarinic acetylcholine receptor hybrid ligands embedding quinuclidine and 1,4-dioxane fragments 179
Fruitful Adrenergic alpha(2C)-Agonism/alpha(2A)-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence 178
NOVEL BIVALENT LIGANDS OF XANOMELINE AND 77-LH-28-1 AS POTENTIAL M1 MUSCARINIC AGONISTS 178
Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models 178
Synthesis and Structure-Activity Relationship Studies in a Series of 2-Substituted 1,3-Dioxolanes Modified at the Cationic Head. 177
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4 chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation 177
DOPAMINE D2, D3, AND D4 RECEPTOR AFFINITIES OF 77-LH-28-1 AND ITS ANALOGUES 176
Dioxane and Oxathiane Nuclei: Suitable Substructures for Muscarinic Agonists 175
Synthesis, molecular modeling, and pharmacological testing of bis-quinolinium cyclophanes: Potent, non-peptidic blockers of the apamin-sensitive Ca2+-activated K+ channel 175
Evaluation of an Agonist Index: Affinity Ratio for Compounds Active on Muscarinic Cholinergic M2 Receptors 174
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma 174
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 173
Synthesis and pharmacological testing of polyaminoquinolines as blockers of the apamin-sensitive Ca2+-activated K+ channel (SKCa) 173
Novel highly potent and selective sigma1 receptor antagonists effectively block the binge eating episode in female rats 172
Agonists and antagonists targeting the different alpha(2)-adrenoceptor subtypes 171
Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity 170
alpha(2)-adrenoreceptors profile modulation. 4. From antagonist, to agonist behavior 169
Rational design of novel I1-imidazoline receptor agonists 168
The 2-substituted imidazoline ring linked to an aromatic moiety by a biatomic bridge: a bioversatile scaffold 168
Might adrenergic α2C-agonist/α2A-antagonist become a novel therapeutic multitarget tool for morphine chronic treatment of pain? 167
Pharmacophore development and 3D-QSAR study of I1 imidazoline binding site ligands 165
MORPHINE TOLERANCE MODULATION INDUCED BY alpha2-ADRENERGIC OR/AND I2 IMIDAZOLINE BINDING SITES LIGANDS 164
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9.From 1,4-benzodioxan to 1,4-dioxane ring as a promising template of novel alpha(1D)-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents. 163
From benzodioxane to 1,4-dioxane scaffold in the design of 5-HT1A serotoninergic full agonists from α1-adrenergic antagonists 162
Assessing the role of ghrelin and the enzyme ghrelin O-acyltransferase (GOAT) system in food reward, food motivation, and binge eating behavior 162
Byciclic dioxolanes as potential antimuscarinic agents 160
Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor 160
Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands 159
Imidazoline nucleus as a biologically versatile scaffold 156
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders 155
Totale 22.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.722
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021800 0 0 0 0 0 0 0 0 0 123 448 229
2021/20221.426 127 330 20 89 109 80 42 98 109 169 87 166
2022/20232.041 240 68 96 297 214 257 14 132 376 121 146 80
2023/20241.438 190 86 95 43 54 132 61 46 146 56 41 488
2024/20254.655 197 102 381 207 129 241 563 1.104 373 293 315 750
2025/20267.359 438 524 1.589 1.059 775 570 1.062 482 449 411 0 0
Totale 27.435